News Releases

Investors

Jasper Therapeutics Announces Updated 90-day Data from Phase 1 Clinical Trial of JSP191 as Targeted Stem Cell Conditioning Agent in Older Patients with Myelodysplastic Syndromes or Acute Myeloid Leukemia Undergoing Hematopoietic Cell Transplantation

May 19, 2021
New efficacy, safety and pharmacokinetic data in first six subjects to be presented in poster session at 2021 ASCO Annual Meeting At 90 days after transplant, measurable residual disease (MRD) as measured by cytogenetics, flow cytometry and next-generation sequencing was negative (undetected) in

Jasper Therapeutics Announces Positive Data from Phase 1 Clinical Trial of JSP191 as Targeted Stem Cell Conditioning Agent in Patients with Myelodysplastic Syndromes or Acute Myeloid Leukemia Undergoing Hematopoietic Cell Transplantation

February 8, 2021
First targeted stem cell factor receptor (anti-CD117) antibody evaluated as a conditioning agent prior to blood stem cell transplantation in patients with hematologic malignancies Data presented as late-breaking abstract at 2021 TCT   REDWOOD CITY, Calif.--( BUSINESS WIRE )--Jasper Therapeutics,
Displaying 11 - 17 of 17
Top

External Link

You are now leaving the Jasper Therapeutics, Inc. site to a 3rd party website. Jasper Therapeutics is not responsible for 3rd party website content.

 

Continue
Cancel